
Loading, please wait...

Loading, please wait...

Postoperative airleak remains a major challenge after lung resection for non-small cell lung cancer. Consequently, many surgical experts often advocate for the fissure last technique to minimize parenchymal damage. However, high-quality clinical evidence comparing this method to the traditional fissure-first approach is limited. Therefore, Vaisitti F et al. conducted a phase III randomized controlled trial to provide clarity on this surgical debate.
The study specifically examined the reduction of airleaks within 48 hours of surgery. To achieve this, researchers randomized 150 patients into two distinct groups. Surprisingly, the results showed no statistically significant difference between the techniques regarding the primary endpoint. Specifically, researchers observed similar airleak rates on postoperative day two in both groups. Furthermore, this trend continued through the fifth postoperative day without significant variation.
In addition, the team analyzed patients with incomplete fissures as a specific subgroup. However, even these high-risk patients showed no significant clinical advantage from the specialized approach. Because of this, chest drain duration and hospital stay remained unchanged for those in the fissure-last group. Consequently, the findings suggest that the fissure last technique does not reliably prevent prolonged airleaks or enhance recovery speed.
Despite theoretical advantages, the strategy does not improve patient recovery outcomes compared to standard methods. Therefore, surgeons should continue to tailor their intraoperative approach to each individual case. In conclusion, while the approach is safe, it may not reduce the postoperative morbidity associated with lung resection.
The fissure last technique is a surgical method where hilar structures are dissected first, leaving the stapling of the lung fissure as the final step. This approach is intended to minimize airleaks by avoiding dissection through fused lung tissue.
No, the recent RCT by Vaisitti F et al. found that using the fissure last technique did not significantly shorten hospital stays or the duration of chest drain placement, even in patients with incomplete fissures.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A trial finds the fissure last technique does not significantly reduce airleaks or shorten hospital stays compared to the standard fissure-first approach....
8 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday